Literature DB >> 30389764

Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.

Kruti B Patel1,2, Shuowei Cai1, Michael Adler3, Brajendra K Singh4, Virinder S Parmar4,2, Bal Ram Singh5,6.   

Abstract

Botulinum neurotoxins (BoNTs), the most poisonous proteins known to humankind, are a family of seven (serotype A to G) immunologically distinct proteins synthesized primarily by different strains of the anaerobic bacterium Clostridium botulinum Being the causative agents of botulism, the toxins block neurotransmitter release by specifically cleaving one of the three soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) proteins, thereby inducing flaccid paralysis. The development of countermeasures and therapeutics against BoNTs is a high-priority research area for public health because of their extreme toxicity and potential for use as biowarfare agents. Extensive research has focused on designing antagonists that block the catalytic activity of BoNTs. In this study, we screened 300 small natural compounds and their analogues extracted from Indian plants for their activity against BoNT serotype A (BoNT/A) as well as its light chain (LCA) using biochemical and cellular assays. One natural compound, a nitrophenyl psoralen (NPP), was identified to be a specific inhibitor of LCA with an in vitro 50% inhibitory concentration (IC50) value of 4.74 ± 0.03 µM. NPP was able to rescue endogenous synaptosome-associated protein 25 (SNAP-25) from cleavage by BoNT/A in human neuroblastoma cells with an IC50 of 12.2 ± 1.7 µM, as well as to prolong the time to the blocking of neutrally elicited twitch tensions in isolated mouse phrenic nerve-hemidiaphragm preparations.IMPORTANCE The long-lasting endopeptidase activity of BoNT is a critical biological activity inside the nerve cell, as it prompts proteolysis of the SNARE proteins, involved in the exocytosis of the neurotransmitter acetylcholine. Thus, the BoNT endopeptidase activity is an appropriate clinical target for designing new small-molecule antidotes against BoNT with the potential to reverse the paralysis syndrome of botulism. In principle, small-molecule inhibitors (SMIs) can gain entry into BoNT-intoxicated cells if they have a suitable octanol-water partition coefficient (log P) value and other favorable characteristics (P. Leeson, Nature 481:455-456, 2012, https://doi.org/10.1038/481455a). Several efforts have been made in the past to develop SMIs, but inhibitors effective under in vitro conditions have not in general been effective in vivo or in cellular models (L. M. Eubanks, M. S. Hixon, W. Jin, S. Hong, et al., Proc Natl Acad Sci U S A 104:2602-2607, 2007, https://doi.org/10.1073/pnas.0611213104). The difference between the in vitro and cellular efficacy presumably results from difficulties experienced by the compounds in crossing the cell membrane, in conjunction with poor bioavailability and high cytotoxicity. The screened nitrophenyl psoralen (NPP) effectively antagonized BoNT/A in both in vitro and ex vivo assays. Importantly, NPP inhibited the BoNT/A light chain but not other general zinc endopeptidases, such as thermolysin, suggesting high selectivity for its target. Small-molecule (nonpeptidic) inhibitors have better oral bioavailability, better stability, and better tissue and cell permeation than antitoxins or peptide inhibitors.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  IC50; botulinum neurotoxin type A; cell-based SNAP-25 assay; high-throughput screening; phrenic nerve-hemidiaphragm preparation

Mesh:

Substances:

Year:  2018        PMID: 30389764      PMCID: PMC6275346          DOI: 10.1128/AEM.01280-18

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  74 in total

Review 1.  Natural products as sources of new drugs over the period 1981-2002.

Authors:  David J Newman; Gordon M Cragg; Kenneth M Snader
Journal:  J Nat Prod       Date:  2003-07       Impact factor: 4.050

2.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

3.  Advanced botulinum toxin techniques against wrinkles in the upper face.

Authors:  Giovanni Salti; Ilaria Ghersetich
Journal:  Clin Dermatol       Date:  2008 Mar-Apr       Impact factor: 3.541

4.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?

Authors:  A Ajay; W P Walters; M A Murcko
Journal:  J Med Chem       Date:  1998-08-27       Impact factor: 7.446

Review 5.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

6.  Fungal bis-Naphthopyrones as Inhibitors of Botulinum Neurotoxin Serotype A.

Authors:  John H Cardellina; Virginia I Roxas-Duncan; Vicki Montgomery; Vanessa Eccard; Yvette Campbell; Xin Hu; Ilja Khavrutskii; Gregory J Tawa; Anders Wallqvist; James B Gloer; Nisarga L Phatak; Ulrich Höller; Ashish G Soman; Biren K Joshi; Sara M Hein; Donald T Wicklow; Leonard A Smith
Journal:  ACS Med Chem Lett       Date:  2012-04-02       Impact factor: 4.345

7.  Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A.

Authors:  S U Nayak; J M Griffiss; R McKenzie; E J Fuchs; R A Jurao; A T An; A Ahene; M Tomic; C W Hendrix; J M Zenilman
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  Analysis of Botulinum Neurotoxin Serotype A Metalloprotease Inhibitors: Analogs of a Chemotype for Therapeutic Development in the Context of a Three-Zone Pharmacophore.

Authors:  James C Burnett; Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald Moir; Sina Bavari; Terry Bowlin
Journal:  Open Access Bioinformatics       Date:  2010-04-01

9.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity.

Authors:  M Adler; J D Nicholson; F Cornille; B E Hackley
Journal:  FEBS Lett       Date:  1998-06-16       Impact factor: 4.124

10.  A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.

Authors:  Laura Goracci; Nathalie Deschamps; Giuseppe Marco Randazzo; Charlotte Petit; Carolina Dos Santos Passos; Pierre-Alain Carrupt; Claudia Simões-Pires; Alessandra Nurisso
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

View more
  2 in total

Review 1.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

Review 2.  An Appraisal of Antidotes' Effectiveness: Evidence of the Use of Phyto-Antidotes and Biotechnological Advancements.

Authors:  Christiana Eleojo Aruwa; Yusuf Ola Mukaila; Abdulwakeel Ayokun-Nun Ajao; Saheed Sabiu
Journal:  Molecules       Date:  2020-03-26       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.